Lupin in licensing pact with US-based Romark Laboratories

Written By Unknown on Rabu, 07 Agustus 2013 | 15.45

Aug 07, 2013, 01.33 PM IST

Lupin will get exclusive rights to distribute and market Alinia for oral suspension, a drug used to treat diarrhea caused by Cryptosporidium and Giardia, two most common protozoal causes of diarrhea.

Like this story, share it with millions of investors on M3

Lupin in licensing pact with US-based Romark Laboratories

Lupin will get exclusive rights to distribute and market Alinia for oral suspension, a drug used to treat diarrhea caused by Cryptosporidium and Giardia, two most common protozoal causes of diarrhea.

Like this story, share it with millions of investors on M3

Lupin in licensing pact with US-based Romark Laboratories

Lupin will get exclusive rights to distribute and market Alinia for oral suspension, a drug used to treat diarrhea caused by Cryptosporidium and Giardia, two most common protozoal causes of diarrhea.

Share  .  Email  .  Print  .  A+A-
Moneycontrol Bureau

Pharma major Lupin has signed a strategic licensing agreement with US-based Romark Laboratories, which will grant the Mumbai-based company exclusive rights to promote, distribute and market Alinia for oral suspension in the US market.

Alinia (nitazoxanide) is used for the treatment of diarrhea caused by Cryptosporidium and Giardia, in patients 1 year of age and older, and is approved by the US Food and Drug Administration, Lupin said.

Cryptosporidium and Giardia are the two most common protozoal causes of diarrhea in the developed and developing world, it said, adding that according to the Centers of Disease Control & Prevention it is estimated that there are 1.2 million cases of Giardiasis and 7.50 lakh cases of Cryptosporidiosis in the US each year.

"Our sales and marketing efforts will commence immediately and we are optimistic that Alinia will contribute to our growth and profitability in the coming quarters and years," said Vinita Gupta, CEO, Lupin Pharmaceuticals Inc.

Lupin shares were down 1.4 percent at Rs 875.55 on NSE in afternoon trade.



Anda sedang membaca artikel tentang

Lupin in licensing pact with US-based Romark Laboratories

Dengan url

https://kesehatanda.blogspot.com/2013/08/lupin-in-licensing-pact-with-us-based.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Lupin in licensing pact with US-based Romark Laboratories

namun jangan lupa untuk meletakkan link

Lupin in licensing pact with US-based Romark Laboratories

sebagai sumbernya

0 komentar:

Posting Komentar

techieblogger.com Techie Blogger Techie Blogger